Vita Fedele

2.0k total citations · 1 hit paper
19 papers, 1.1k citations indexed

About

Vita Fedele is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Vita Fedele has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Vita Fedele's work include Genomics and Chromatin Dynamics (5 papers), Cancer Genomics and Diagnostics (3 papers) and Gene expression and cancer classification (3 papers). Vita Fedele is often cited by papers focused on Genomics and Chromatin Dynamics (5 papers), Cancer Genomics and Diagnostics (3 papers) and Gene expression and cancer classification (3 papers). Vita Fedele collaborates with scholars based in Italy, United States and Germany. Vita Fedele's co-authors include Christopher C. Benz, David G. Ginzinger, Michael Mattie, Chris Haqq, Linda Wong, Jessica Bowers, Gary K. Scott, Robert Getts, Davide Melisi and Angelo Paradiso and has published in prestigious journals such as Nature Communications, Cancer Research and Clinical Cancer Research.

In The Last Decade

Vita Fedele

19 papers receiving 1.1k citations

Hit Papers

Optimized high-throughput microRNA expression profiling p... 2006 2026 2012 2019 2006 100 200 300 400 500

Peers

Vita Fedele
Kathy A. Toy United States
Wei Wen Teo United States
Nishan Thilaganathan United States
Yi Sang China
Kathy A. Toy United States
Vita Fedele
Citations per year, relative to Vita Fedele Vita Fedele (= 1×) peers Kathy A. Toy

Countries citing papers authored by Vita Fedele

Since Specialization
Citations

This map shows the geographic impact of Vita Fedele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vita Fedele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vita Fedele more than expected).

Fields of papers citing papers by Vita Fedele

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vita Fedele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vita Fedele. The network helps show where Vita Fedele may publish in the future.

Co-authorship network of co-authors of Vita Fedele

This figure shows the co-authorship network connecting the top 25 collaborators of Vita Fedele. A scholar is included among the top collaborators of Vita Fedele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vita Fedele. Vita Fedele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Forés-Martos, Jaume, Vita Fedele, Sten Cornelissen, et al.. (2021). Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression. npj Breast Cancer. 7(1). 118–118. 6 indexed citations
2.
Merz, Valeria, Camilla Zecchetto, Alessandro Cavaliere, et al.. (2021). Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Frontiers in Oncology. 11. 638360–638360. 44 indexed citations
3.
Merz, Valeria, Camilla Zecchetto, Raffaela Santoro, et al.. (2020). Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. Clinical Cancer Research. 26(17). 4661–4669. 19 indexed citations
4.
Fedele, Vita & Davide Melisi. (2020). Permissive State of EMT: The Role of Immune Cell Compartment. Frontiers in Oncology. 10. 587–587. 20 indexed citations
5.
Contarelli, Serena, Vita Fedele, & Davide Melisi. (2020). HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies. Cancers. 12(11). 3299–3299. 24 indexed citations
6.
Montenegro, Raquel Carvalho, Alison Howarth, Alessandro Ceroni, et al.. (2020). Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib. Oncotarget. 11(5). 535–549. 32 indexed citations
7.
Merz, Valeria, Camilla Zecchetto, Francesca Simionato, et al.. (2020). A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. Therapeutic Advances in Medical Oncology. 12. 3863552929–3863552929. 30 indexed citations
8.
Leavy, Olivia C., Nicola H. Dryden, Sarah Maguire, et al.. (2018). Capture Hi-C identifies putative target genes at 33 breast cancer risk loci. Nature Communications. 9(1). 1028–1028. 72 indexed citations
9.
Fedele, Vita, Fangping Dai, Dieter Henrik Heiland, et al.. (2017). Epigenetic Regulation of ZBTB18 Promotes Glioblastoma Progression. Molecular Cancer Research. 15(8). 998–1011. 30 indexed citations
10.
Tommasi, Stefania, Giuseppina Iannelli, Filippo Menolascina, et al.. (2011). Determining and Interpreting New Predictive Rules for Breast Cancer Familial Inheritance. OMICS A Journal of Integrative Biology. 15(3). 125–131. 1 indexed citations
11.
Fedele, Vita, Jane Fridlyand, Ritu Roydasgupta, et al.. (2007). Mutations in TP53 and associated genomic abnormalities are dependent on breast cancer estrogen receptor status and patient age. Cancer Research. 67. 2962–2962. 1 indexed citations
12.
Yau, Christina, Vita Fedele, Ritu Roydasgupta, et al.. (2007). Aging Impacts Transcriptome but not Genome of Hormone-dependent Breast Cancers. eScholarship (California Digital Library). 1 indexed citations
13.
Tommasi, Stefania, Anita Mangia, Rosanna Lacalamita, et al.. (2007). Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins. International Journal of Cancer. 120(10). 2078–2085. 130 indexed citations
14.
Tommasi, Stefania, Vita Fedele, Rosanna Lacalamita, et al.. (2007). 655Val and 1170Pro ERBB2 SNPs in Familial Breast Cancer Risk and BRCA1 Alterations. Analytical Cellular Pathology. 29(3). 241–248. 19 indexed citations
15.
Yau, Christina, Vita Fedele, Ritu Roydasgupta, et al.. (2007). Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Research. 9(5). R59–R59. 57 indexed citations
16.
Mattie, Michael, Christopher C. Benz, Jessica Bowers, et al.. (2006). Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.. Molecular Cancer. 5(1). 24–24. 589 indexed citations breakdown →
17.
Benz, Christopher C., Vita Fedele, Fan Xu, et al.. (2006). Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers. Genes Chromosomes and Cancer. 45(11). 983–994. 8 indexed citations
18.
Tommasi, Stefania, Vita Fedele, Rosanna Lacalamita, et al.. (2004). Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Letters. 209(2). 215–222. 19 indexed citations
19.
Tommasi, Stefania, et al.. (2003). ErbB2 and the antimetastatic nm23/NDP kinase in regulating serum induced breast cancer invasion. International Journal of Molecular Medicine. 12(1). 131–4. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026